Log in or Sign up for Free to view tailored content for your specialty!
Spondyloarthropathies News
Work disability due to inflammatory arthritis greater among lower-paid, manual jobs
People who work lower-paid, manual-labor jobs are more likely to discontinue employment in the first 5 years after an early inflammatory arthritis diagnosis, vs. those who work in managerial or professional capacities, according to data.
Rheumatologists influential in smoking cessation for patients with ankylosing spondylitis
A rheumatologist’s decision to ask about tobacco use may potentially be the leading factor in whether a patient with ankylosing spondylitis quits smoking, according to data published in Cureus.
Log in or Sign up for Free to view tailored content for your specialty!
Adalimumab biosimilar SB5 shows high persistence, no new safety signals through 48 weeks
Patients receiving the adalimumab biosimilar SB5 demonstrated high persistence, consistent effectiveness and no new safety signals through 48 weeks, according to data published in BioDrugs.
Odds of opioid use in autoimmune rheumatic disease decreased 15% annually after 2014
SAN DIEGO — The likelihood of opioid use among patients with autoimmune rheumatic disease has decreased annually by 15% since 2014, according to data presented at ACR Convergence 2023.
‘This gives us more leeway’: Intravenous secukinumab effective in axial spondyloarthritis
SAN DIEGO — An intravenous formulation of secukinumab met all primary efficacy endpoints, with an attractive safety profile, in patients with axial spondyloarthritis over 52 weeks, according to data presented at ACR Convergence 2023.
Ixekizumab reduces erosion, increases backfill scores in radiographic axial SpA
SAN DIEGO — Biologic-naïve patients with radiographic axial spondylarthritis who receive ixekizumab for 16 weeks demonstrate reduced erosion scores and increased backfill scores, according to data presented at ACR Convergence 2023.
Medicare fails to ‘keep up with’ Medicaid, private market on infliximab biosimilar uptake
SAN DIEGO — Compared with Medicaid and private insurance, Medicare has lagged significantly in adopting infliximab biosimilars despite the multiple options now available, according to data presented at ACR Convergence 2023.
Rheumatology referrals often lack key details of patients’ inflammatory arthritis
Key details expressing arthralgia duration, morning stiffness or joint examination findings are often missing from rheumatology referral letters for inflammatory arthritis, according to data published in Rheumatology Advances in Practice.
Bimekizumab sustains axial spondyloarthritis improvements at 52 weeks
Patients with axial spondyloarthritis who receive bimekizumab demonstrate sustained improvement through 52 weeks and a safety profile consistent with shorter trials, according to data published in the Annals of the Rheumatic Diseases.
Newly diagnosed psoriatic disease associated with autoimmune disease risk
Newly diagnosed psoriatic disease may bring with it a significantly increased risk for autoimmune disease incidences, according to a study.
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read